

Francesca Minoia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4834417/publications.pdf>

Version: 2024-02-01

56
papers

2,410
citations

331670

21
h-index

233421

45
g-index

58
all docs

58
docs citations

58
times ranked

2847
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome" by Zhang <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e100-e100.	0.9	2
2	Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. <i>Rheumatology</i> , 2022, 61, 1621-1629.	1.9	5
3	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. <i>Ophthalmology and Therapy</i> , 2022, 11, 899-911.	2.3	14
4	Acute Retinal Necrosis: Clinical Features, Diagnostic Pitfalls, Treatment, and Outcome of an Insidious Disease in Children. Case Report and Review of the Literature. <i>Frontiers in Pediatrics</i> , 2022, 10, 854325.	1.9	3
5	Infection-Triggered Hyperinflammatory Syndromes in Children. <i>Children</i> , 2022, 9, 564.	1.5	0
6	Response to "Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease" by Wang <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e146-e146.	0.9	1
7	Absence of Severe Complications From SARS-CoV-2 Infection in Children With Rheumatic Diseases Treated With Biologic Drugs. <i>Journal of Rheumatology</i> , 2021, 48, 1343.1-1344.	2.0	43
8	Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 561-566.e4.	2.9	90
9	Juvenile idiopathic arthritis in Harlequin ichthyosis, a rare combination or the clinical spectrum of the disease? Report of a child treated with etanercept and review of the literature. <i>Pediatric Rheumatology</i> , 2021, 19, 80.	2.1	4
10	Cytokine storm syndrome in a young patient with cystic fibrosis. <i>Pediatric Pulmonology</i> , 2021, 56, 3435-3437.	2.0	2
11	Thrombotic Microangiopathy Associated with Macrophage Activation Syndrome: A Multinational Study of 23 Patients. <i>Journal of Pediatrics</i> , 2021, 235, 196-202.	1.8	7
12	Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis. <i>Lancet Rheumatology</i> , The, 2021, 3, e690-e697.	3.9	121
13	Development and Preliminary Validation of an Electromyography-Scoring Protocol for the Assessment and Grading of Muscle Involvement in Patients With Juvenile Idiopathic Inflammatory Myopathies. <i>Pediatric Neurology</i> , 2021, 124, 6-10.	2.1	2
14	Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases. <i>Pediatric Rheumatology</i> , 2020, 18, 56.	2.1	6
15	Macrophage Activation Syndrome in Childhood Inflammatory Disorders: Diagnosis, Genetics, Pathophysiology, and Treatment. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 245-259.	1.4	0
16	COVID-19 multidisciplinary high dependency unit: the Milan model. <i>Respiratory Research</i> , 2020, 21, 260.	3.6	22
17	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. <i>Rheumatology</i> , 2020, 59, 3505-3514.	1.9	39
18	Use of anakinra in severe COVID-19: A case report. <i>International Journal of Infectious Diseases</i> , 2020, 96, 607-609.	3.3	58

#	ARTICLE	IF	CITATIONS
19	Chronic non-bacterial osteomyelitis: a retrospective international study on clinical manifestations and response to treatment. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1255-1262.	0.8	3
20	Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1357-1362.	0.9	74
21	Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 345-349.	2.1	47
22	Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 416-421.	2.0	41
23	When neonatal inflammation does not mean infection: an early-onset mevalonate kinase deficiency with interstitial lung disease. <i>Clinical Immunology</i> , 2019, 205, 25-28.	3.2	10
24	AB1063â€¦INTERSTITIAL LUNG DISEASE IN A NEWBORN AFFECTED BY MEVALONIC ACIDURIA. , 2019, , .		0
25	THU0527â€¦RISK SCORE OF MACROPHAGE ACTIVATION SYNDROME IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0
26	FRI0565â€¦A MULTINATIONAL STUDY OF THROMBOTIC MICROANGIOPATHY IN MACROPHAGE ACTIVATION SYNDROME: A DREADFUL CONDITION WHICH IS LIKELY UNDER-RECOGNIZED. , 2019, , .		2
27	FRI0547â€¦DEVELOPMENT AND INITIAL VALIDATION OF THE SYSTEMIC JADAS, A NEW COMPOSITE DISEASE ACTIVITY SCORE FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		1
28	AB0938â€¦EFFICACY AND SAFETY OF BIOLOGICAL THERAPY WITH ETANERCEPT IN A CASE OF SEVERE POLIARTHRITIS ASSOCIATED TO HARLEQUIN ICTHIOSIS. , 2019, , .		0
29	Fostering the application of the MS score in systemic juvenile idiopathic arthritis. Response to: â€œMS score in systemic juvenile idiopathic arthritis: suitable for routine use?â€™ by Chi et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrheumdis-2019-216067.	0.9	2
30	Extracorporeal blood purification techniques in children with hyper-inflammatory syndromes: a clinical overview. <i>Minerva Anestesiologica</i> , 2019, 85, 531-542.	1.0	7
31	Criteria for Cytokine Storm Syndromes. , 2019, , 61-79.		0
32	Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 3-5.	2.0	5
33	ABCC6 mutations and early onset stroke: Two cases of a typical Pseudoxanthoma Elasticum. <i>European Journal of Paediatric Neurology</i> , 2018, 22, 725-728.	1.6	15
34	Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 409-419.	3.4	96
35	Inflammatory myopathy in a patient with collagen VI mutations. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 166-167.	1.1	0
36	High-dose ustekinumab for severe childhood deficiency of interleukin-36 receptor antagonist (DITRA). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-211805.	0.9	21

#	ARTICLE	IF	CITATIONS
37	Widening the Heterogeneity of Leigh Syndrome: Clinical, Biochemical, and Neuroradiologic Features in a Patient Harboring a NDUFA10 Mutation. <i>JIMD Reports</i> , 2017, 37, 37-43.	1.5	13
38	Biologics in juvenile idiopathic arthritis: a narrative review. <i>European Journal of Pediatrics</i> , 2017, 176, 1147-1153.	2.7	35
39	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. <i>Journal of Pediatrics</i> , 2017, 189, 72-78.e3.	1.8	50
40	CD70 Deficiency due to a Novel Mutation in a Patient with Severe Chronic EBV Infection Presenting As a Periodic Fever. <i>Frontiers in Immunology</i> , 2017, 8, 2015.	4.8	31
41	Macrophage Activation Syndrome. , 2017, , 275-292.		0
42	IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. <i>Frontiers in Pharmacology</i> , 2016, 7, 467.	3.5	39
43	Macrophage Activation Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2016, , 85-106.	0.1	1
44	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2016, 68, 566-576.	5.6	427
45	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000161.	3.8	57
46	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 481-489.	0.9	338
47	Long-term efficacy of IL-1 blockers in PAPA patients. <i>Pediatric Rheumatology</i> , 2015, 13, .	2.1	2
48	Clinical features and correct diagnosis of macrophage activation syndrome. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1043-1053.	3.0	60
49	Dissecting the Heterogeneity of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 994-1001.	2.0	59
50	Macrophage Activation Syndrome. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 927-941.	2.2	121
51	Long-term efficacy of etanercept in ADA2 deficiency. <i>Pediatric Rheumatology</i> , 2014, 12, .	2.1	4
52	Dissecting the heterogeneity of macrophage activation syndrome. <i>Pediatric Rheumatology</i> , 2014, 12, .	2.1	0
53	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2014, 12, .	2.1	6
54	Chronic active EBV infection mimicking periodic fever syndromes: a new challenge for the paediatrician. <i>Pediatric Rheumatology</i> , 2014, 12, .	2.1	0

#	ARTICLE	IF	CITATIONS
55	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A Multinational, Multicenter Study of 362 Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 3160-3169.	5.6	322
56	Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 2871-2880.	5.6	101